- Home
- APLD vs SNDX Comparison
APLD vs SNDX Comparison
Compare APLD & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLD
- SNDX
- Stock Information
- Founded
- APLD 2001
- SNDX 2005
- Country
- APLD United States
- SNDX United States
- Employees
- APLD N/A
- SNDX N/A
- Industry
- APLD Investment Bankers/Brokers/Service
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- APLD Finance
- SNDX Health Care
- Exchange
- APLD Nasdaq
- SNDX Nasdaq
- Market Cap
- APLD 1.3B
- SNDX 1.1B
- IPO Year
- APLD N/A
- SNDX 2016
- Fundamental
- Price
- APLD $10.43
- SNDX $9.48
- Analyst Decision
- APLD Strong Buy
- SNDX Strong Buy
- Analyst Count
- APLD 11
- SNDX 11
- Target Price
- APLD $12.64
- SNDX $35.91
- AVG Volume (30 Days)
- APLD 82.2M
- SNDX 1.8M
- Earning Date
- APLD 04-14-2025
- SNDX 07-31-2025
- Dividend Yield
- APLD N/A
- SNDX N/A
- EPS Growth
- APLD N/A
- SNDX N/A
- EPS
- APLD N/A
- SNDX N/A
- Revenue
- APLD $221,192,000.00
- SNDX $43,722,000.00
- Revenue This Year
- APLD $34.51
- SNDX $426.77
- Revenue Next Year
- APLD $3.33
- SNDX $98.31
- P/E Ratio
- APLD N/A
- SNDX N/A
- Revenue Growth
- APLD 53.70
- SNDX N/A
- 52 Week Low
- APLD $3.01
- SNDX $8.58
- 52 Week High
- APLD $15.42
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- APLD 54.46
- SNDX 36.85
- Support Level
- APLD $10.89
- SNDX $11.00
- Resistance Level
- APLD $11.78
- SNDX $11.83
- Average True Range (ATR)
- APLD 1.41
- SNDX 0.58
- MACD
- APLD -0.27
- SNDX -0.11
- Stochastic Oscillator
- APLD 32.76
- SNDX 10.31
About APLD Applied Digital Corporation
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments; Data Center Hosting Business, Cloud Services Business, and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business which operates data centers to provide energized space to crypto mining customers.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.